Key facts
- This page summarizes Stephen Berenson's Form 4 filing for Moderna, Inc. (MRNA).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 May 2024, 17:10.
Stephen Berenson - 03 May 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Director
- Issuer ticker
- MRNA
- Reported as of
- 03 May 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 May 2024, 17:10:08 UTC
- Prior SEC filing
- 08 Apr 2024
- Next SEC filing
- 03 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Berenson filed Form 4 for Moderna, Inc. (MRNA) on 07 May 2024.
Change
- Previous filing in this sequence was filed on 08 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +732
- Change %
- +3.4%
- Price
- Shares after
- 22,203
- Date
- 03 May 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -732
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 732
- Exercise price
- Footnotes
- F1, F2
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +7,557
- Change %
- Price
- $0.000000
- Shares after
- 7,557
- Date
- 06 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,557
- Exercise price
- $122.13
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
The shares subject to this restricted stock unit award vested in full on May 3, 2024.
Footnote F3
This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.